Lineage Cell Therapeutics
LCTX
75 hedge funds and large institutions have $50.2M invested in Lineage Cell Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 20 closing their positions.
6,600% more call options, than puts
Call options by funds: $67K | Put options by funds: $1K
4% more capital invested
Capital invested by funds: $48.5M → $50.2M (+$1.7M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.47% less ownership
Funds ownership: 37.18% → 35.72% (-1.5%)
20% less funds holding
Funds holding: 94 → 75 (-19)
46% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 24
90% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$356K |
| 2 |
Millennium Management
New York
|
+$303K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$112K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$81.1K |
| 5 |
Two Sigma Advisers
New York
|
+$40.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$718K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$665K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$284K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$219K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$136K |
LCTX Hedge Fund Activity: Q3 2020 in Review
75 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2020, worth a combined $50.2M — up 3.5% from $48.5M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LCTX and 2 opened new positions — a net loss of 18 holders — while 24 trimmed existing stakes and 13 added.
The largest buyer was Defender Capital, adding an estimated $356K. The largest seller was Jane Street, cutting an estimated $718K.
- 75 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2020, down from 94 in Q2 2020.
- Funds reported $50.2M of Lineage Cell Therapeutics stock for Q3 2020, up 3.5% quarter-over-quarter.
- 2 funds opened new Lineage Cell Therapeutics positions in Q3 2020 and 20 closed out, a net change of -18 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2020 was Defender Capital, an estimated $356K added.
- The largest Lineage Cell Therapeutics seller in Q3 2020 was Jane Street, an estimated $718K sold.
Based on aggregated 13F filings for Q3 2020.